Cancer Diagnostics – Products

PacBio enhances HiFi sequencing with AI-based methylation detection, enabling accurate native 5hmC and strand-specific 5mC analysis.

Biodesix, in partnership with Bio-Rad, contributed to the ctMoniTR Project, which demonstrated that changes in circulating tumor DNA (ctDNA) can predict cancer treatment outcomes.

This compendium provides researchers with a portfolio of electrophoresis instruments to support quality control and automation for a more reliable NGS workflow.

Ultima Genomics has launched the "Count on Us" initiative, offering 3 trillion DNA sequencing reads to researchers at academic, public or non-profit institutions in the U.S. and Canada.

This application note explores how electrophoretic methods surpass the capabilities of traditional methods to accurately distinguish between cfDNA and contaminating high molecular weight (HMW) DNA, making them ideal for cfDNA quality control.

Zymo Research celebrates a legal victory as the court denies QIAGEN’s motion in an ongoing antitrust and patent dispute.

Labor Dr. Wisplinghoff, and Genomic Testing Cooperative (GTC), are excited to announce the launch of their collaboration.

This application note provides data-driven insights for optimizing cfDNA workflows, from initial sample input to final sequencing parameters.

Build your own instrument – fully automated cell imaging and picking. Use the instrument configurator to design your very own customized CellCelector, perfectly tailored to meet your unique needs.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced updates on its oncology assay portfolio and regulatory milestones, ahead of its presence at the AMP 2024 meeting.